407 related articles for article (PubMed ID: 26841017)
21. Splenic irradiation as a component of a reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in myelofibrosis with massive splenomegaly.
Ito T; Akagi K; Kondo T; Kawabata H; Ichinohe T; Takaori-Kondo A
Tohoku J Exp Med; 2012 Dec; 228(4):295-9. PubMed ID: 23117264
[TBL] [Abstract][Full Text] [Related]
22. Myelofibrosis: an update on drug therapy in 2016.
Bose P; Verstovsek S
Expert Opin Pharmacother; 2016 Dec; 17(18):2375-2389. PubMed ID: 27774820
[TBL] [Abstract][Full Text] [Related]
23. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2016 Dec; 91(12):1262-1271. PubMed ID: 27870387
[TBL] [Abstract][Full Text] [Related]
24. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2014 Sep; 89(9):915-25. PubMed ID: 25124313
[TBL] [Abstract][Full Text] [Related]
25. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
26. Myelofibrosis: an update on current pharmacotherapy and future directions.
Cervantes F; Martinez-Trillos A
Expert Opin Pharmacother; 2013 May; 14(7):873-84. PubMed ID: 23514013
[TBL] [Abstract][Full Text] [Related]
27. The evolving treatment paradigm in myelofibrosis.
Mesa RA
Leuk Lymphoma; 2013 Feb; 54(2):242-51. PubMed ID: 22793267
[TBL] [Abstract][Full Text] [Related]
28. New strategies in myelofibrosis: the evolving paradigm of disease pathogenesis, prognostication and treatment.
Palandri F; Auteri G; Baccarani M
Hematol Oncol; 2017 Jun; 35(2):145-150. PubMed ID: 27510853
[TBL] [Abstract][Full Text] [Related]
29. Treatment options for hydroxyurea-refractory disease complications in myeloproliferative neoplasms: JAK2 inhibitors, radiotherapy, splenectomy and transjugular intrahepatic portosystemic shunt.
Mishchenko E; Tefferi A
Eur J Haematol; 2010 Sep; 85(3):192-9. PubMed ID: 20528907
[TBL] [Abstract][Full Text] [Related]
30. Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.
Randhawa J; Ostojic A; Vrhovac R; Atallah E; Verstovsek S
J Hematol Oncol; 2012 Aug; 5():43. PubMed ID: 22852872
[TBL] [Abstract][Full Text] [Related]
31. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis.
Tefferi A; Pardanani A; Gangat N
Haematologica; 2023 Nov; 108(11):2919-2932. PubMed ID: 36861402
[TBL] [Abstract][Full Text] [Related]
32. Anemia in myelofibrosis: Current and emerging treatment options.
Passamonti F; Harrison CN; Mesa RA; Kiladjian JJ; Vannucchi AM; Verstovsek S
Crit Rev Oncol Hematol; 2022 Dec; 180():103862. PubMed ID: 36332787
[TBL] [Abstract][Full Text] [Related]
33. How I treat myelofibrosis.
Tefferi A
Blood; 2011 Mar; 117(13):3494-504. PubMed ID: 21200024
[TBL] [Abstract][Full Text] [Related]
34. Beyond JAK inhibitor therapy in myelofibrosis.
Odenike O
Hematology Am Soc Hematol Educ Program; 2013; 2013():545-52. PubMed ID: 24319230
[TBL] [Abstract][Full Text] [Related]
35. Modern management of splenomegaly in patients with myelofibrosis.
Tremblay D; Schwartz M; Bakst R; Patel R; Schiano T; Kremyanskaya M; Hoffman R; Mascarenhas J
Ann Hematol; 2020 Jul; 99(7):1441-1451. PubMed ID: 32417942
[TBL] [Abstract][Full Text] [Related]
36. Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options.
Mesa RA; Barosi G; Cervantes F; Reilly JT; Tefferi A
Best Pract Res Clin Haematol; 2006; 19(3):495-517. PubMed ID: 16781486
[TBL] [Abstract][Full Text] [Related]
37. Myelofibrosis-Related Anemia: Current and Emerging Therapeutic Strategies.
Naymagon L; Mascarenhas J
Hemasphere; 2017 Dec; 1(1):e1. PubMed ID: 31723730
[TBL] [Abstract][Full Text] [Related]
38. Novel therapeutics and targets in myelofibrosis.
Waksal JA; Harrison CN; Mascarenhas JO
Leuk Lymphoma; 2022 May; 63(5):1020-1033. PubMed ID: 34852713
[TBL] [Abstract][Full Text] [Related]
39. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
Talpaz M; Kiladjian JJ
Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
[TBL] [Abstract][Full Text] [Related]
40. Alleviating anemia and thrombocytopenia in myelofibrosis patients.
Cervantes F; Correa JG; Hernandez-Boluda JC
Expert Rev Hematol; 2016 May; 9(5):489-96. PubMed ID: 26891375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]